Terminated PHASE2 INTERVENTIONAL 3-arm NCT05556265

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata

Sponsor: Bristol-Myers Squibb

Conditions Alopecia Areata

Interventions Deucravacitinib Placebo

Updated 21 times since 2022 Last updated: May 14, 2025 Started: Nov 8, 2022 Primary completion: Jan 6, 2024 Completion: May 16, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business objectives have changed

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

Other Alopecia Areata trials with similar outcome

Browse all Alopecia Areata trials

A PHASE2 clinical study on Alopecia Areata, this trial is terminated or withdrawn. The trial is conducted by Bristol-Myers Squibb and has accumulated 21 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

21 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Jun 2025 — Sep 2025 [monthly]

Terminated PHASE2
Mar 2025 — Jun 2025 [monthly]

Terminated PHASE2
Sep 2024 — Mar 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2

▶ Show 16 earlier versions

Jun 2024 — Jul 2024 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Apr 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE2
Feb 2024 — Apr 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE2
Dec 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE2
Sep 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2
Oct 2022 — Dec 2022 [monthly]

Not Yet Recruiting PHASE2
Sep 2022 — Oct 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Carlton, Australia , Chapel Hill, United States , Clinton Township, United States , Hamamatsu, Japan , Houston, United States , Kogarah, Australia , Kōtoku, Japan , Markham, Canada , Mitaka-Shi, Japan and 18 more locations